Strategies to manage hepatitis C virus (HCV) disease burden

Authors

WEDEMEYER H. DUBERG A. S. BUTI M. ROSENBERG W. M. FRANKOVA S. ESMAT G. ÖRMECI N. VAN VLIERBERGHE H. GSCHWANTLER M. AKARCA U. ALEMAN S. BALIK I. BERG T. BIHL F. BILODEAU M. BLASCO A. J. MELLO C. E. Brandao BRUGGMANN P. CALINAS F. CALLEJA J. L. CHEINQUER H. CHRISTENSEN P. B. CLAUSEN M. COELHO H. S. M. CORNBERG M. CRAMP M. E. DORE G. J. DOSS W. EL-SAYED M. H. ERGÖR G. ESTES C. FALCONER K. FÉLIX J. FERRAZ M. L. G. FERREIRA P. R. GARCÍA-SAMANIEGO J. GERSTOFT J. GIRIA J. A. GONÇALES F. L. Jr. PESSÔA M. Guimaraes HÉZODE C. HINDMAN S. J. HOFER H. HUSA Petr IDILMAN R. KABERG M. KAITA K. D. E. KAUTZ A. KAYMAKOGLU S. KRAJDEN M. KRARUP H. LALEMAN W. LAVANCHY D. LÁZARO P. MARINHO R. T. MAROTTA P. MAUSS S. CORREA M. C. Mendes MORENO C. MÜLLHAUPT B. MYERS R. P. NEMECEK V. OVREHUS A. L. H. PARKES J. PELTEKIAN K. M. RAMJI A. RAZAVI H. REIS N. ROBERTS S. K. ROUDOT-THORAVAL F. RYDER S. D. SARMENTO-CASTRO R. SARRAZIN C. SEMELA D. SHERMAN M. SHIHA G. E. SPERL J. STÄRKEL P. STAUBER R. E. THOMPSON A. J. URBANEK P. DAMME P. Van THIEL I. van VANDIJCK D. VOGEL W. WAKED I. WEIS N. WIEGAND J. YOSRY A. ZEKRY A. NEGRO F. SIEVERT W. GOWER E.

Year of publication 2014
Type Article in Periodical
Magazine / Source JOURNAL OF VIRAL HEPATITIS
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1111/jvh.12249
Field Epidemiology, infectious diseases and clinical immunology
Keywords diagnosis; epidemiology; HCV; mortality; treatment; scenarios; prevalence; incidence; hepatitis C; disease burden
Description The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

You are running an old browser version. We recommend updating your browser to its latest version.

More info